Jun 06, 2023 / 02:20PM GMT
Matt Phipps - William Blair - Analyst
Hi, everyone. My name is Matt Phipps. I'm a biotech analyst here at William Blair covering Dynavax. Thanks all for coming to our 43rd Annual Growth Stock Conference. Happy to have Ryan Spencer, the CEO of Dynavax, here. Bunch of us, the team is here as well for the breakout session.
But Ryan is going to walk us through kind of the story. And I do think it's an important time to look at the story, given what has been some really impressive growth of HEPLISAV recently and a bunch of pipeline readouts even today.
So with that, Ryan, go ahead and take over.
Ryan Spencer - Dynavax Technologies Corporation - CEO
Thank you, Matt. Thanks for having us. Like Matt said, my name is Ryan Spencer, I have the pleasure of being the CEO of Dynavax.
Before we begin, I want to recognize that the presentation contains forward-looking statements that have certain risk and uncertainties that are highlighted in our risk factors in our Form 10-Q and 10-K, our SEC filings, which we encourage you to review.
So
Dynavax Technologies Corp at William Blair Growth Stock Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers